Immunogen NASDAQ: IMGN
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology.
Name | Immunogen |
Ticker | IMGN |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Price | 7.21 |
52W Low/High | 2.12 / 7.66 |
Market cap | 1.3 B |
1Y Total Return |
58.11%
Strong |
1Y Volatility |
88.96%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology.
Details
Ticker | IMGN |
Name | Immunogen |
ISIN | US45253H1014 |
CUSIP | 45253H101 |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/15/21
Close Price | 7.21 |
52W Low/High | 2.12 / 7.66 |
Market cap | 1.3 B |
1Y Total Return |
58.11%
Strong |
1Y Volatility |
88.96%
High Risk |
Beta | 2.64 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | -77.7% |
Cash from Op. / Cur. Liabilities | -1.20 |
Diluted Earnings / Share | -0.40 |
ROE | - |
ROIC | - |
Price / Revenue | 13.8 |
Price / Book | -29.3 |
Price / CF | -10.5 |
Current Ratio | 2.2 |
Cur.Liabilities / Tot.Liabilities | 0.3 |
Financial Leverage | - |
in Mils USD |
rolling-year up to September
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
91
|
51
|
79
|
90
|
53
|
87
|
|
Gross Profit |
91
|
51
|
79
|
90
|
53
|
87
|
|
R&D |
101
|
132
|
171
|
134
|
146
|
119
|
|
EBITDA |
-69
|
-146
|
-132
|
-107
|
-149
|
-67
|
|
Operating Income |
-50
|
-141
|
-131
|
-78
|
-135
|
-61
|
|
Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
175
|
148
|
147
|
93
|
87
|
87
|
|
EPS exc. Extra |
-0.40
|
-1.03
|
-0.98
|
-1.31
|
-1.79
|
-0.84
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
248
|
254
|
340
|
226
|
231
|
286
|
|
Cash, Eq & Invt ShortTerm |
188
|
204
|
303
|
195
|
196
|
248
|
|
Total Current Assets |
219
|
226
|
323
|
207
|
207
|
262
|
|
Total Non-Current Assets |
29
|
28
|
17
|
19
|
24
|
24
|
|
Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Liabilities |
291
|
340
|
293
|
337
|
354
|
274
|
|
Total Current Liabilities |
100
|
88
|
70
|
74
|
56
|
36
|
|
Long Term Debt |
191
|
252
|
223
|
263
|
298
|
238
|
|
Shareholder equity |
-43
|
-86
|
47
|
-111
|
-123
|
12
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
-120
|
-97
|
-155
|
1
|
-141
|
-68
|
|
Depreciation |
2
|
4
|
8
|
6
|
6
|
5
|
|
Cash from Investing |
3
|
-4
|
-4
|
-1
|
-8
|
-9
|
|
Capex |
3
|
4
|
4
|
1
|
8
|
9
|
|
Cash from Financing |
101
|
2
|
267
|
-1
|
97
|
203
|
|
Stock Issued |
101
|
2
|
267
|
0
|
1
|
9
|
|
Debt (LT) Issued |
0
|
0
|
0
|
0
|
97
|
0
|
|
Free Cash Flow |
-75
|
-130
|
-143
|
-102
|
-125
|
-90
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
2.2
|
2.6
|
4.6
|
2.8
|
3.7
|
7.3
|
|
Financial Leverage D/E |
-
|
-
|
0.04
|
-
|
-
|
0.00
|
|
Return on Capital Avg |
-
|
-
|
-
|
-
|
-
|
-
|
|
Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available